Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$82.70
1.772.19%
al cierre: Nov 26, 4:00 PM EST
$82.54
-0.16-0.19%
After hour: 4:08 PM EST
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Ionis Pharmaceuticals Inc tiene un precio objetivo de consenso de $79.13 basado en las calificaciones de 25 analistas. El máximo es $110, emitido por HC Wainwright & Co. el noviembre 10, 2025. El mínimo es $39, emitido por Redburn Atlantic el marzo 31, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por HC Wainwright & Co., Piper Sandler y TD Cowen el noviembre 10, 2025, noviembre 4, 2025 y octubre 30, 2025, respectivamente. Con un precio objetivo promedio de $95.33 entre HC Wainwright & Co., Piper Sandler y TD Cowen, hay una 15.50% upside implícita para Ionis Pharmaceuticals Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
HC Wainwright & Co.
Piper Sandler
TD Cowen
Morgan Stanley
Barclays
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Ionis Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/10/2025 | 33.27% | HC Wainwright & Co. | $100 → $110 | Maintains | Buy | |||
11/04/2025 | -6.71% | Piper Sandler | $70 → $77 | Maintains | Overweight | |||
10/30/2025 | 19.94% | TD Cowen | $59 → $99 | Maintains | Buy | |||
10/30/2025 | 13.88% | Morgan Stanley | $90 → $94 | Maintains | Overweight | |||
10/30/2025 | 15.1% | Barclays | $80 → $95 | Maintains | Overweight | |||
10/30/2025 | 21.15% | HC Wainwright & Co. | $95 → $100 | Maintains | Buy | |||
10/30/2025 | -0.65% | RBC Capital | $80 → $82 | Maintains | Outperform | |||
10/30/2025 | 7.83% | Raymond James | $85 → $89 | Reiterates | Strong Buy → Strong Buy | |||
10/30/2025 | 9.04% | Needham | $78 → $90 | Maintains | Buy | |||
10/16/2025 | 9.04% | Morgan Stanley | $86 → $90 | Maintains | Overweight | |||
10/08/2025 | -5.5% | Needham | $70 → $78 | Maintains | Buy | |||
10/08/2025 | 9.04% | Oppenheimer | $84 → $90 | Maintains | Outperform | |||
10/08/2025 | -3.08% | JP Morgan | $49 → $80 | Upgrade | Neutral → Overweight | |||
10/08/2025 | 15.1% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
10/06/2025 | -18.83% | Stifel | $43 → $67 | Maintains | Hold | |||
09/26/2025 | -21.25% | Goldman Sachs | $45 → $65 | Upgrade | Sell → Neutral | |||
09/23/2025 | 4.19% | Morgan Stanley | $71 → $86 | Maintains | Overweight | |||
09/23/2025 | -3.08% | Barclays | $78 → $80 | Maintains | Overweight | |||
09/23/2025 | 11.46% | Guggenheim | $90 → $92 | Maintains | Buy | |||
09/23/2025 | 0.56% | B of A Securities | $81 → $83 | Maintains | Buy | |||
09/23/2025 | 15.1% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
09/04/2025 | -3.08% | RBC Capital | $70 → $80 | Maintains | Outperform | |||
09/03/2025 | 1.77% | Citigroup | $69 → $84 | Maintains | Buy | |||
09/03/2025 | -45.48% | Goldman Sachs | $40 → $45 | Maintains | Sell | |||
09/03/2025 | -15.19% | BMO Capital | $40 → $70 | Upgrade | Market Perform → Outperform | |||
09/03/2025 | -5.5% | Barclays | $58 → $78 | Maintains | Overweight | |||
09/02/2025 | 16.31% | Jefferies | $83 → $96 | Maintains | Buy | |||
09/02/2025 | -15.19% | Needham | $55 → $70 | Maintains | Buy | |||
09/02/2025 | 15.1% | HC Wainwright & Co. | $70 → $95 | Maintains | Buy | |||
08/25/2025 | -40.63% | JP Morgan | $48 → $49 | Maintains | Neutral | |||
08/25/2025 | -33.37% | Needham | $55 → $55 | Reiterates | Buy → Buy | |||
08/22/2025 | -16.4% | Citigroup | $65 → $69 | Maintains | Buy | |||
08/22/2025 | -21.25% | Piper Sandler | $62 → $65 | Maintains | Overweight | |||
08/22/2025 | -29.73% | Barclays | $57 → $58 | Maintains | Overweight | |||
08/22/2025 | -0.65% | Wells Fargo | $77 → $82 | Maintains | Overweight | |||
08/22/2025 | -15.19% | HC Wainwright & Co. | $65 → $70 | Maintains | Buy | |||
08/12/2025 | -44.27% | UBS | $45 → $46 | Maintains | Neutral | |||
07/31/2025 | -22.46% | Raymond James | $60 → $64 | Maintains | Strong Buy | |||
07/31/2025 | -24.88% | Morgan Stanley | $55 → $62 | Upgrade | Equal-Weight → Overweight | |||
07/31/2025 | -21.25% | HC Wainwright & Co. | $50 → $65 | Maintains | Buy | |||
07/01/2025 | -30.94% | Barclays | $51 → $57 | Upgrade | Equal-Weight → Overweight | |||
06/26/2025 | -39.42% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
06/12/2025 | -41.85% | JP Morgan | $45 → $48 | Maintains | Neutral | |||
05/20/2025 | -39.42% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/01/2025 | -22.46% | Guggenheim | $65 → $64 | Maintains | Buy | |||
05/01/2025 | -39.42% | HC Wainwright & Co. | $45 → $50 | Maintains | Buy | |||
04/30/2025 | -33.37% | Needham | $60 → $55 | Maintains | Buy | |||
04/15/2025 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
04/08/2025 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
04/07/2025 | -45.48% | HC Wainwright & Co. | → $45 | Initiates | → Buy | |||
04/03/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
03/31/2025 | -52.75% | Redburn Atlantic | → $39 | Initiates | → Neutral | |||
03/24/2025 | -45.48% | JP Morgan | $47 → $45 | Maintains | Neutral | |||
03/11/2025 | -43.06% | JP Morgan | $51 → $47 | Maintains | Neutral | |||
02/20/2025 | -22.46% | Citigroup | $67 → $64 | Maintains | Buy | |||
02/20/2025 | -15.19% | RBC Capital | $70 → $70 | Reiterates | Outperform → Outperform | |||
02/20/2025 | -45.48% | BMO Capital | $60 → $45 | Maintains | Market Perform | |||
02/20/2025 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
01/15/2025 | -15.19% | RBC Capital | $70 → $70 | Reiterates | Outperform → Outperform | |||
12/20/2024 | -27.31% | Needham | $60 → $60 | Maintains | Buy | |||
11/14/2024 | -24.88% | Piper Sandler | $65 → $62 | Maintains | Overweight | |||
11/07/2024 | -6.71% | Wells Fargo | $82 → $77 | Maintains | Overweight | |||
11/07/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
10/09/2024 | -21.25% | Guggenheim | $70 → $65 | Maintains | Buy | |||
09/26/2024 | -15.19% | RBC Capital | $70 → $70 | Reiterates | Outperform → Outperform | |||
08/26/2024 | -33.37% | JP Morgan | $50 → $55 | Maintains | Neutral | |||
08/02/2024 | -15.19% | Guggenheim | $64 → $70 | Maintains | Buy | |||
08/02/2024 | -55.17% | Goldman Sachs | $33 → $37 | Maintains | Sell | |||
08/02/2024 | -38.21% | Barclays | $45 → $51 | Maintains | Equal-Weight | |||
08/02/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
08/02/2024 | -27.31% | BMO Capital | $67 → $60 | Downgrade | Outperform → Market Perform | |||
07/24/2024 | -24.88% | Leerink Partners | $53 → $62 | Upgrade | Market Perform → Outperform | |||
07/23/2024 | -28.52% | TD Cowen | $54 → $59 | Maintains | Buy | |||
07/23/2024 | -17.62% | B of A Securities | $67 → $68 | Maintains | Buy | |||
07/22/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
07/16/2024 | -18.83% | B of A Securities | $64 → $67 | Maintains | Buy | |||
07/16/2024 | -9.13% | Jefferies | $29 → $75 | Upgrade | Underperform → Buy | |||
06/27/2024 | -35.79% | Stifel | $50 → $53 | Maintains | Hold | |||
06/14/2024 | — | Bernstein | — | Upgrade | Underperform → Market Perform | |||
06/03/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
05/08/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
05/08/2024 | -0.65% | Wells Fargo | $85 → $82 | Maintains | Overweight | |||
04/10/2024 | — | Wolfe Research | — | Upgrade | Peer Perform → Outperform | |||
04/09/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
04/09/2024 | -9.13% | Oppenheimer | $72 → $75 | Maintains | Outperform | |||
03/06/2024 | -12.77% | Oppenheimer | $65 → $72 | Maintains | Outperform | |||
02/26/2024 | -21.25% | Oppenheimer | $63 → $65 | Reinstates | → Outperform | |||
02/22/2024 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
02/22/2024 | -23.67% | Piper Sandler | $62 → $63 | Maintains | Overweight | |||
02/01/2024 | -33.37% | JP Morgan | $52 → $55 | Maintains | Neutral | |||
01/26/2024 | -15.19% | RBC Capital | $65 → $70 | Maintains | Outperform | |||
01/18/2024 | -24.88% | Piper Sandler | $60 → $62 | Maintains | Overweight | |||
01/02/2024 | -24.88% | B of A Securities | $52 → $62 | Upgrade | Neutral → Buy | |||
12/19/2023 | -27.31% | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
12/18/2023 | -39.42% | Stifel | $45 → $50 | Maintains | Hold | |||
11/17/2023 | -27.31% | Needham | → $60 | Reiterates | Buy → Buy | |||
11/03/2023 | -66.08% | Goldman Sachs | $25 → $28 | Maintains | Sell | |||
11/03/2023 | -41.85% | Morgan Stanley | $45 → $48 | Maintains | Equal-Weight | |||
10/23/2023 | -37% | B of A Securities | $33 → $52 | Upgrade | Underperform → Neutral | |||
10/05/2023 | -21.25% | RBC Capital | → $65 | Reiterates | Outperform → Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Ionis Pharmaceuticals (IONS)?
El último precio objetivo de Ionis Pharmaceuticals (NASDAQ:IONS) fue comunicado por HC Wainwright & Co. el noviembre 10, 2025. La firma de analistas fijó un precio objetivo para $110.00 que espera IONS a rise dentro de 12 meses (un posible 33.27% upside). 60 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Ionis Pharmaceuticals (IONS)?
La última calificación de analistas para Ionis Pharmaceuticals (NASDAQ:IONS) fue proporcionada por HC Wainwright & Co., y Ionis Pharmaceuticals mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Ionis Pharmaceuticals (IONS)?
La última revisión al alza de Ionis Pharmaceuticals Inc se produjo en octubre 8, 2025, cuando JP Morgan elevó su precio objetivo a $80. JP Morgan anteriormente tenía a neutral para Ionis Pharmaceuticals Inc.
¿Cuándo fue la última revisión a la baja de Ionis Pharmaceuticals (IONS)?
La última revisión a la baja de Ionis Pharmaceuticals Inc se produjo en agosto 2, 2024, cuando BMO Capital cambió su precio objetivo de $67 a $60 para Ionis Pharmaceuticals Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Ionis Pharmaceuticals (IONS)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Ionis Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Ionis Pharmaceuticals se registró el noviembre 10, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 10, 2026.
¿Es correcta la calificación de los analistas sobre Ionis Pharmaceuticals (IONS)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Ionis Pharmaceuticals (IONS) fue un mantuvo con un precio objetivo de $100.00 a $110.00. El precio actual al que cotiza Ionis Pharmaceuticals (IONS) es de $82.54, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.